MAPT and Cognitive impairment: It identifies AD with the same accuracy as tau PET [3–5] and CSF p-tau181 [4] and associates with development of AD dementia in cognitively unimpaired (CU) individuals and in those with mild cognitive impairment (MCI) [4], as well as in carriers of mutations causing familial AD [6].